Auckland, New Zealand, 16 September 2004 - Fisher & Paykel Healthcare Corporation Limited (NZX:FPH, ASX:FPH) advises that the Board has resolved to subdivide the Company’s existing ordinary shares. Each one existing ordinary share in the Company will be subdivided into five ordinary shares. The Board considers that the subdivision will provide additional liquidity in the market for the Company’s shares.
The record date for determining the subdivision will be Friday, 1 October 2004. The share subdivision will take effect following the close of business on that day. Shares will be available for trading on a subdivided basis when the markets open on Monday, 4 October 2004.
All shares will carry equal voting rights and entitlements to future dividends.
All shareholders holding shares at 7.00 pm (New Zealand time) today will be sent a letter by the
Company advising them of the subdivision.
As a result of the ordinary share subdivision the Company advises that it will reorganise options issued under the Company’s Option Plans. Between 2 November 2001 and 16 September 2004 the Company issued a total of 3,503,900 options under the Plans, of which 3,388,802 options remain outstanding. In accordance with the Plan Rules and both the ASX and NZX Listing Rules, the outstanding options issued will be adjusted as follows:
These adjustments will take effect simultaneously with the ordinary share subdivision.
Share Buy Back
In accordance with Listing Rule 7.6.2 and ASX requirements, Fisher & Paykel Healthcare advises that it intends to extend its existing share buy back programme which expires on 30 September 2004 for a further six months to 31 March 2005 on the following terms (being the same terms of the existing buy back programme except for the extension of time).
The Company has appointed UBS New Zealand to provide financial advice and assistance in relation to the buy back and the acquisitions pursuant to the buy back.
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of heated humidification products and systems for use in respiratory care and the treatment of obstructive sleep apnea. It also offers an innovative range of patient warming devices and neonatal care products. The company’s products are sold in over 90 countries worldwide.
Further information can be obtained by contacting Michael Daniell MD/CEO on +64 9 574 0161 or Tony Barclay CFO on +64 9 574 0119 at Fisher & Paykel Healthcare Corporation Limited or by visiting the company’s website at www.fphcare.com
Fisher & Paykel Healthcare Notification of Share Subdivision and Extension of Share Buyback Programme
Evidence and guidance for delivering Optiflow NHF, proven respiratory support for your patients.
Providing Optimal Humidity for intubated patients
Featuring under nose NIV masks and full face NIV masks, with vented and non-vented options to suit your hospital NIV mask needs.
Establish effective spontaneous breathing or assist ventilation of the lungs
Respiratory support that replaces spontaneous breathing
Noninvasive respiratory support that provides a continuous distending pressure
Noninvasive respiratory support that delivers high flows of blended air and oxygen
Delivering warm, humidified carbon dioxide in laparoscopic and open surgery
Designed to work in harmony with the way patients naturally breathe while they sleep
F&P SleepStyle - designed to strike the balance between comfort and effective treatment